"Dr. Kenneth Chapman founded Inspiration Research Limited (IRL) in 2003. Inspiration Research Limited specializes in clinical studies with patients diagnosed with asthma, heart disease and COPD. - Asthma management strategies - Patient Education - Chronic Obstructive Pulmonary Disease - Alpha-1 Antitrypsin Deficiency In addition, IRL operates a pulmonary function test laboratory that is occasionally open on Saturdays. Pulmonary function tests are valuable tools for doctors to diagnose patients with asthma, COPD, and other respiratory disease. Inspiration Research Limited has participated in developing of several leading treatment for asthma and COPD patients, such as Onbrez and Seebri Breezhaler."

During the past decade, Inspiration Research Limited conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 7 clinical trials were completed, i.e. on average, 53.8% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Inspiration Research Limited" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Gilead Sciences" with 3 trials sponsored, "Grifols Therapeutics LLC" with 2 trials sponsored, "Vertex Pharmaceuticals Incorporated" with 2 trials sponsored and "Arrowhead Pharmaceuticals" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Inspiration Research Limited" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Laval University" with 1 trials as a collaborator, "McGill University" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Inspiration Research Limited" are "Asthma" (5 trials), "Alpha 1-Antitrypsin Deficiency" (2 trials), "Chronic Obstructive Pulmonary Disease" (2 trials), "Emphysema" (2 trials) and "HBV" (2 trials). Many other conditions were trialed in "Inspiration Research Limited" in a lesser frequency.

Most popular intervention types in "Inspiration Research Limited" are "Drug" (14 trials), "Biological" (4 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Lebrikizumab" (3 trials), "Alpha-1 MP" (2 trials), "TAF" (2 trials) and "TAF Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Inspiration Research Limited" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Inspiration Research Limited". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 11 completed trials in Inspiration Research Limited, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Inspiration Research Limited, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".